ImmunoCellular Therapeutics Ltd (IMUC):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoCellular Therapeutics Ltd (IMUC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7351
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd (IMUC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ImmunoCellular Therapeutics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deal Details 10
Equity Offering 10
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 10
ImmunoCellular Therapeutics Files for Rights Offering 12
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 13
ImmunoCellular Therapeutics Ltd – Key Competitors 15
ImmunoCellular Therapeutics Ltd – Key Employees 16
ImmunoCellular Therapeutics Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
Aug 13, 2018: ImmunoCellular Therapeutics provides corporate update and reports second quarter 2018 financial results 18
May 14, 2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results 20
Mar 13, 2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 21
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 22
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 23
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 24
Other Significant Developments 26
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition 26
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
ImmunoCellular Therapeutics Ltd, Medical Equipment, Key Facts, 2017 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ImmunoCellular Therapeutics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Deals By Market, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 10
ImmunoCellular Therapeutics Files for Rights Offering 12
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 13
ImmunoCellular Therapeutics Ltd, Key Competitors 15
ImmunoCellular Therapeutics Ltd, Key Employees 16
ImmunoCellular Therapeutics Ltd, Subsidiaries 17
ImmunoCellular Therapeutics Ltd, Joint Venture 17

List of Figures
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[ImmunoCellular Therapeutics Ltd (IMUC):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsubishi Tanabe Pharma Corp (4508):製薬・医療:M&Aディール及び事業提携情報
    Summary Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, d …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Trent Ltd (TRENT):企業の財務・戦略的SWOT分析
    Trent Ltd (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SoftBank Group Corp:企業の戦略・SWOT・財務分析
    SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report Summary SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • WesternZagros Resources Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary WesternZagros Resources ULC (WesternZagros), formerly WesternZagros Resources Ltd, a subsidiary of Crest Energy International Ltd, is an oil and gas company that acquires, develops, explores and produces crude oil and natural gas. The company holds production sharing contracts with the Kurdi …
  • AxoGen Inc (AXGN):医療機器:M&Aディール及び事業提携情報
    Summary AxoGen Inc (AxoGen), formerly LecTec Corp is a provider of surgical solutions to measure and monitor nerve functions. The company offers products such as AxoTouch two-point discriminator, AxoGuard nerve connector, Avance nerve graft, AcroVal NSTMS and AxoGuard nerve protector products, among …
  • Maanshan Iron & Steel Company Limited:企業の戦略・SWOT・財務情報
    Maanshan Iron & Steel Company Limited - Strategy, SWOT and Corporate Finance Report Summary Maanshan Iron & Steel Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Core-Mark Holding Company, Inc.:企業の戦略・SWOT・財務分析
    Core-Mark Holding Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Core-Mark Holding Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NSK Ltd (6471):企業の財務・戦略的SWOT分析
    NSK Ltd (6471) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • BioCryst Pharmaceuticals Inc (BCRX)-製薬・医療分野:企業M&A・提携分析
    Summary BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. Biocryst integrat …
  • Rizal Commercial Banking Corp (RCB):企業の財務・戦略的SWOT分析
    Summary Rizal Commercial Banking Corp (RCBC) is a commercial and financial banking service provider that offers corporate, commercial, and consumer banking, cash management, treasury, and remittance products and services. The company’s electronic banking services include mobile banking, internet ban …
  • The Walsh Group:企業の戦略・SWOT・財務分析
    The Walsh Group - Strategy, SWOT and Corporate Finance Report Summary The Walsh Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tsumura & Co.:企業の戦略・SWOT・財務情報
    Tsumura & Co. - Strategy, SWOT and Corporate Finance Report Summary Tsumura & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Metanomics Health GmbH:企業の製品パイプライン分析2018
    Summary Metanomics Health GmbH (Metanomics), a subsidiary of BASF SE, is a biotech company that provides metabolic biomarker identification and validation solutions. The company offers analysis of metabolites for various applications in pharma and biotech, biobanking, academia, food and feed industr …
  • Onconova Therapeutics Inc (ONTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect he …
  • Sanochemia Pharmazeutika AG (SAC)-医療機器分野:企業M&A・提携分析
    Summary Sanochemia Pharmazeutika AG (Sanochemia) is a specialty pharmaceutical company that develops and manufactures of innovative drugs in selected indication areas such as neurodegeneration, pain and cancer, as well as diagnostic products based on contrast media. The company’s product portfolio i …
  • S-Oil Corporation Inc (010950):石油・ガス:M&Aディール及び事業提携情報
    Summary S-Oil Corporation Inc (S-Oil) is a service driven company that operates in the petroleum and petrochemical industry. The company imports and exports crude oil; as well as manufactures and sells oil refining products, petrochemical products and lube products. S-Oil also produces a wide range …
  • Alarko Contracting Group:企業の戦略・SWOT・財務分析
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Repros Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Repros Therapeutics Inc (Repros), formerly Zonagen Inc, a subsidiary of Allergan PLC, is a biopharmaceutical company that develops and markets drugs to treat hormonal and reproductive system disorders. The company’s pipeline product includes enclomiphene and proellex. Its enclomiphene is an …
  • GeoVax Labs Inc (GOVX)-製薬・医療分野:企業M&A・提携分析
    Summary GeoVax Labs Inc (GeoVax) is a clinical-stage biotechnology company, which develops human vaccines for diseases caused by HIV, cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆